|
KR101313702B1
(ko)
*
|
2005-02-03 |
2013-10-04 |
와이어쓰 |
제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
|
|
EP2505591A1
(en)
|
2005-02-11 |
2012-10-03 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for detecting a drug resistant EGFR mutant
|
|
US12366585B2
(en)
|
2006-05-18 |
2025-07-22 |
Caris Mpi, Inc. |
Molecular profiling of tumors
|
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
BRPI0808551B1
(pt)
|
2007-03-01 |
2022-04-05 |
Symphogen A/S |
Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
|
|
US9340601B2
(en)
|
2007-03-01 |
2016-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Splice variants of the EGF receptor
|
|
PT2412828E
(pt)
*
|
2007-03-13 |
2013-08-02 |
Amgen Inc |
Mutações k-ras e b-raf e terapia com anticorpos anti-egfr
|
|
GB2453173A
(en)
*
|
2007-09-28 |
2009-04-01 |
Dxs Ltd |
Polynucleotide primers
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
CL2009000843A1
(es)
*
|
2008-04-11 |
2009-07-24 |
Galaxy Biotech Llc |
Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
|
|
BRPI0914790A2
(pt)
|
2008-06-17 |
2015-10-20 |
Wyeth Llc |
uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
|
|
ATE544063T1
(de)
*
|
2008-07-17 |
2012-02-15 |
Koninkl Philips Electronics Nv |
Nanoporenvorrichtung und verfahren zur nukleinsäureanalyse
|
|
WO2010022736A2
(en)
|
2008-08-29 |
2010-03-04 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
|
CN101445832B
(zh)
*
|
2008-12-23 |
2011-09-14 |
广州益善生物技术有限公司 |
Pik3ca基因突变的检测探针、液相芯片及其检测方法
|
|
EP3722810A3
(en)
*
|
2009-02-11 |
2021-01-13 |
Caris MPI, Inc. |
Molecular profiling of tumors
|
|
EP2475789A4
(en)
*
|
2009-09-09 |
2013-12-18 |
Quintiles Transnat Corp |
METHOD FOR PREDICTING THE RESPONSIBILITY OF A DISEASE OR A SLEEPING TO A RECEPTOR SYRINOIN INHIBITORY BY ANALYSIS OF MUTATIONS IN PIK3CA
|
|
JP5891172B2
(ja)
*
|
2010-07-07 |
2016-03-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
正常乳腺上皮細胞からの腫瘍細胞の製造方法
|
|
US20120164641A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Roche Molecular Systems, Inc. |
Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
|
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
|
AU2012253525B2
(en)
*
|
2011-05-10 |
2016-09-22 |
Brunangelo Falini |
Hairy cell leukemia biomarkers and methods of using same
|
|
EP2554551A1
(en)
*
|
2011-08-03 |
2013-02-06 |
Fundacio Institut mar d'Investigacions Médiques (IMIM) |
Mutations in the epidermal growth factor receptor gene
|
|
US20140005119A1
(en)
*
|
2012-06-28 |
2014-01-02 |
Case Western Reserve University |
COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
|
|
CN105264084A
(zh)
*
|
2013-01-14 |
2016-01-20 |
中央研究院 |
静默egfr表达的脱氧核糖核酸酶
|
|
CN103739713B
(zh)
*
|
2013-12-10 |
2016-03-09 |
吴炯 |
一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
GB2521355A
(en)
*
|
2013-12-17 |
2015-06-24 |
Kymab Ltd |
Human targets I
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
WO2015092393A2
(en)
*
|
2013-12-17 |
2015-06-25 |
Kymab Limited |
Human targets
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
CN105779480B
(zh)
*
|
2016-03-24 |
2020-03-20 |
成都康景生物科技有限公司 |
一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US9980967B1
(en)
|
2017-03-16 |
2018-05-29 |
National Chiao Tung University |
Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
|
|
CN108047308A
(zh)
*
|
2018-02-02 |
2018-05-18 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108047309A
(zh)
*
|
2018-02-07 |
2018-05-18 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108250268A
(zh)
*
|
2018-02-08 |
2018-07-06 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108409832A
(zh)
*
|
2018-03-07 |
2018-08-17 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108218960A
(zh)
*
|
2018-03-07 |
2018-06-29 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108218959A
(zh)
*
|
2018-03-07 |
2018-06-29 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108218961A
(zh)
*
|
2018-03-19 |
2018-06-29 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108440649A
(zh)
*
|
2018-05-31 |
2018-08-24 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108752424A
(zh)
*
|
2018-06-04 |
2018-11-06 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108440650A
(zh)
*
|
2018-06-04 |
2018-08-24 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108440651A
(zh)
*
|
2018-06-08 |
2018-08-24 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
TW202019421A
(zh)
*
|
2018-07-31 |
2020-06-01 |
大陸商蘇州亞盛藥業有限公司 |
Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
|
|
CN109485721A
(zh)
*
|
2018-11-23 |
2019-03-19 |
杜学明 |
一种获得肿瘤特异性t细胞受体的方法
|
|
RU2706116C1
(ru)
*
|
2018-12-26 |
2019-11-14 |
Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) |
Способ прогнозирования течения аденокарциномы легкого
|
|
KR102370550B1
(ko)
*
|
2019-01-11 |
2022-03-08 |
주식회사 진캐스트 |
Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
|
|
WO2020145754A1
(ko)
*
|
2019-01-11 |
2020-07-16 |
주식회사 진캐스트 |
유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법
|
|
KR102310819B1
(ko)
*
|
2019-01-11 |
2021-10-12 |
주식회사 진캐스트 |
Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
|
|
BR112021016149A2
(pt)
|
2019-02-26 |
2021-10-13 |
Janssen Biotech, Inc. |
Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
|
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
|
EP4005593A4
(en)
*
|
2019-07-24 |
2023-08-16 |
Sinocelltech Ltd. |
MULTIVARIABLE DOSING METHOD FOR USE IN THE TREATMENT OF HIGH EGFR EXPRESSION CANCER
|
|
JP7783182B2
(ja)
|
2020-02-12 |
2025-12-09 |
ヤンセン バイオテツク，インコーポレーテツド |
ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
|